Nimotuzumab in Treatment of Infiltrating Squamous Cell Carcinoma of Tongue

Alex A. Prasad^*

Chennai Cancer Care Hospital, Chennai, India.

DOI: 10.4236/jct.2015.62015                

Abstract

A 50-year male patient presented to outpatient department with a mass on tongue associated with pain. A plain computerised tomography scan done on 17/01/13 revealed mild growth on lateral border of tongue with an enlarged jugulo-digastric lymph node measuring 1.8 × 1 cm. Excision of tongue was done and sent for histopathological examination which revealed infiltrating squamous cell carcinoma. The patient was treated with 2 cycles of Induction chemotherapy with cisplatin and paclitaxel administered in q3w schedule. Induction chemotherapy was followed by concurrent chemoradiotherapy with 6 cycles of nimotuzumab 200 mg and cisplatin 20 mg given weekly along with 60 gy/30 fractions of radiation using IMRT. Latest CT scan done on 20/01/2014 revealed no evidence of disease (NED).

Keywords

Nimotuzumab, Epidermal Growth Factor Receptor (EGFR), Transforming Growth Factor α (TGFα)

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Morestein, H. (1919) La Cure Radicale du Cancer de la Langue. Journal Chirurgie, 15, 221-252.
[2]	Butlin, H.T. (1909) An Address on the Results of Operations for Carcinoma of the Tongue, with an Analysis of 197 Cases: Delivered before the International Surgical Society in Brussels. British Medical Journal, 1, 1.b2-1.b6.
[3]	Douglas, Q., et al. (1921) Treatment of Carcinoma of the Tongue. Annals of Surgery, 73, 716-723. http://dx.doi.org/10.1097/00000658-192106000-00005
[4]	Globocan (2015) Fact Sheets by Population—Globocan—IARC. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
[5]	Iype, E.M., Pandey, M., Mathew, A., Thomas, G., Sebastian, P. and Nair, M.K. (2001) Squamous Cell Carcinoma of the Tongue among Young Indian Adults. Neoplasia, 3, 273-277. http://dx.doi.org/10.1038/sj.neo.7900172
[6]	Ciardiello, F. and Tortora, G. (2008) EGFR Antagonists in Cancer Treatment. The New England Journal of Medicine, 358, 1160-1174. http://dx.doi.org/10.1056/NEJMra0707704
[7]	Akashi, Y., Okamoto, I., Iwasa, T., et al. (2008) Enhancement of the Antitumor Activity of Ionising Radiation by Nimotuzumab, a Humanised Monoclonal Antibody to the Epidermal Growth Factor Receptor, in Non-Small Cell Lung Cancer Cell Lines of Differing Epidermal Growth Factor Receptor Status. British Journal of Cancer, 98, 749-755. http://dx.doi.org/10.1038/sj.bjc.6604222
[8]	Crombet, T., Torres, L., Neninger, E., et al. (2003) Pharmacological Evaluation of Humanized Anti-Epidermal Growth Factor Receptor, Monoclonal Antibody h-R3, in Patients with Advanced Epithelial-Derived Cancer. Journal of Immunotherapy, 26, 139-148. http://dx.doi.org/10.1097/00002371-200303000-00006
[9]	Crombet, T., Osorio, M., Cruz, T., et al. (2004) Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 in Combination with Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer Patients. Journal of Clinical Oncology, 22, 1646-1654. http://dx.doi.org/10.1200/JCO.2004.03.089